To date, the only M.S. treatments on the market come in the form of an injection or an infusion. Excitingly, laquinimod, the potentially first-ever oral therapy for M.S. is undergoing its second Global Phase III Trial. And — they are looking for qualified patients to join the trial. Enrollments began on July 17th.
The following information was supplied to me by Erica Tursi, who represents the firm promoting Iaquinimod (email@example.com). I’ve agreed to post the information here for readers. (This is lengthy information, but it all seemed important and relevant and I certainly didn’t want to be the one to edit out some important clause). If you like what you read and want to enroll in the Bravo Trial, call 1-800-840-5601. More information will come soon on how to enroll in the Allegro Trial, although there is a number supplied below as well. Deep breath — and read on, and on, and on!
TEVA ENROLLS PATIENTS FOR A SECOND LARGE GLOBAL PHASE III TRIAL OF ORAL LAQUINIMOD